Should I buy or sell Gland Pharma?

The average broker rating on Gland Pharma is Hold. The breakup of analyst rating is given below - 2 analysts have given a strong sell rating 3 analysts have given a sell rating 1 analysts have given a hold rating 0.00 analysts have given a buy rating 4 analysts have given a strong buy rating

Is Gland Pharma a good stock to invest in?

Gland Pharma can be analyzed on the following key metrics - TTM P/E: 41.61 Sector P/E: 26.62 Dividend Yield: 1.38% D/E ratio: -

Gland Pharma Share Price

Sector: Biotechnology & Drugs

Powered by

1414.50 -36.85 (-2.54%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 1411.00

Today’s High 1455.15

52 Week Low 1200.00

52 Week High 2220.95

Key Metrics

Market Cap (In Cr) 23304.79
Beta 0.62
Div. Yield (%) 1.38
P/B 2.73
TTM P/E 41.61
Peg Ratio -3.62
Sector P/E 26.62
Open Price 1447.9
Prev Close 1451.35

View All Metrics

Gland Pharma Analysis

Price Analysis

1 Week

-0.1%
3 Months

-7.07%
6 Month

-9.84%
YTD

-18.63%
1 Year

-16.72%

Risk Meter

36% Low risk
36% Moderate risk
36% Balanced Risk
36% High risk
36% Extreme risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings
Current
1 W Ago
1 M Ago
3 M Ago

Strong Buy
4
4
4
4

Buy
0.00
0.00
0.00
0.00

Hold
1
1
1
1

Sell
3
3
3
3

Strong Sell
2
2
2
2

Total
10
10
10
10

Gland Pharma News

Buying the dip? ICICI Pru Mutual Fund buys 4 lakh shares of THIS pharma company despite 10% fall in April

Premium

ICICI Pru MF buys 4 lakh shares of THIS pharma co despite 10% dip in April

2 min read . 16 Apr 2025

Fall in pharma stocks dragged the Nifty Pharma index more than 2% lower. (Photo: Bloomberg)

Premium

Pharma stocks fall up to 5% as Donald Trump to announce pharma tariffs

1 min read . 09 Apr 2025

Trump Reciprocal Tariffs: Pharma shares rise up to 13% on tariff exemption; Gland Pharma, Aurobindo Pharma lead gainers

Premium

Pharma shares rise up to 13% on Trump's tariff exemption; Gland Pharma lead gain

3 min read . 03 Apr 2025

Of India's pharma exports of $27.9 billion in FY24, $8.7 billion or 31% were to the US. Photo: Dhiraj Singh/Bloomberg

Premium

Indian pharma companies escape Trump’s reciprocal tariffs, for now

4 min read . 03 Apr 2025

View More News

Gland Pharma Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
5664.72

Selling/ General/ Admin Expenses Total
2012.94

Depreciation/ Amortization
344.57

Other Operating Expenses Total
55.4

Total Operating Expense
4676.22

Operating Income
988.51

Net Income Before Taxes
1132.54

Net Income
772.46

Diluted Normalized EPS
46.88

Period
2023

Total Revenue
3624.6

Selling/ General/ Admin Expenses Total
810

Depreciation/ Amortization
146.74

Other Operating Expenses Total
9.73

Total Operating Expense
2802.95

Operating Income
821.65

Net Income Before Taxes
1054.58

Net Income
781.04

Diluted Normalized EPS
50.26

Period
2022

Total Revenue
4400.71

Selling/ General/ Admin Expenses Total
694.61

Depreciation/ Amortization
110.3

Other Operating Expenses Total
3.79

Total Operating Expense
3000.67

Operating Income
1400.03

Net Income Before Taxes
1618.55

Net Income
1211.66

Diluted Normalized EPS
73.65

Period
2021

Total Revenue
3462.88

Selling/ General/ Admin Expenses Total
590.16

Depreciation/ Amortization
98.78

Other Operating Expenses Total
0.12

Total Operating Expense
2259.43

Operating Income
1203.45

Net Income Before Taxes
1334.81

Net Income
996.96

Diluted Normalized EPS
62.99

Period
2020

Total Revenue
2633.24

Selling/ General/ Admin Expenses Total
514.31

Depreciation/ Amortization
94.59

Other Operating Expenses Total
4.31

Total Operating Expense
1772.36

Operating Income
860.88

Net Income Before Taxes
992.87

Net Income
772.86

Diluted Normalized EPS
46.5

Period
2019

Total Revenue
2044.2

Selling/ General/ Admin Expenses Total
432.64

Depreciation/ Amortization
82.12

Other Operating Expenses Total
1.05

Total Operating Expense
1439.82

Operating Income
604.38

Net Income Before Taxes
686.28

Net Income
451.86

Diluted Normalized EPS
28.48

Period
2018

Total Revenue
1622.89

Selling/ General/ Admin Expenses Total
340.2

Depreciation/ Amortization
78.37

Other Operating Expenses Total
1.62

Total Operating Expense
1165.98

Operating Income
456.92

Net Income Before Taxes
501.47

Net Income
321.05

Diluted Normalized EPS
21.33

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Gland Pharma Technical

Moving Average SMA

5 Day1462.14
10 Day1441.67
20 Day1491.87

50 Day1525.75
100 Day1619.26
300 Day1735.31

Gland Pharma Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Syngene International
616.85
-12.8
-2.03
960
608
24830.49

J B Chemicals And Pharmaceutical
1605.9
29.85
1.89
2029
1303
24962.19

Gland Pharma
1414.5
-36.85
-2.54
2220.95
1200
23304.79

Wockhardt
1392.95
-3.4
-0.24
1678.6
489.2
22632.51

Eris Lifesciences
1478.65
10.7
0.73
1593
815.5
20256.49

Gland Pharma Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

03-Feb-25
Quarterly Results

04-Nov-24
Quarterly Results

06-Aug-24
Quarterly Results

22-May-24
Audited Results & Final Dividend

14-Feb-24
Quarterly Results

06-Nov-23
Quarterly Results

07-Aug-23
Quarterly Results

18-May-23
Audited Results & A.G.M.

23-Jan-23
Quarterly Results

26-Oct-22
Quarterly Results

Meeting Date
Announced on
Purpose

01-Apr-25
28-Feb-25
POM

11-Mar-25
07-Feb-25
POM

10-Dec-24
08-Nov-24
POM

30-Aug-24
22-May-24
AGM

20-Nov-23
19-Oct-23
POM

31-Aug-23
01-Aug-23
AGM

08-Mar-23
06-Feb-23
POM

30-Aug-22
19-May-22
AGM

22-Apr-22
21-Mar-22
POM

26-Aug-21
17-May-21
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

22-May-24
16-Aug-24
16-Aug-24
20

View All

Company Profile

ABOUT Gland Pharma

Industry Biotechnology & Drugs
ISIN INE068V01023
BSE Code 543245
NSE Code GLAND

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

MANAGEMENT

Srinivas Sadu Executive Chairman of the Board
Shyamakant Giri Chief Executive Officer
Ravi Mitra Chief Financial Officer
Sampath Pallerlamudi Compliance Officer, Company Secretary

GLAND PHARMA SUMMARY

Gland Pharma is trading 2.54% lower at Rs 1414.50 as compared to its last closing price. Gland Pharma has been trading in the price range of 1455.15 & 1411.00. Gland Pharma has given -18.63% in this year & -0.1% in the last 5 days.

Gland Pharma has TTM P/E ratio 41.61 as compared to the sector P/E of 26.62. There are 10 analysts who have initiated coverage on Gland Pharma. There are 4 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.

The company posted a net profit of 204.69 Crores in its last quarter.

Listed peers of Gland Pharma include Syngene International (-2.03%), J B Chemicals And Pharmaceutical (1.89%), Gland Pharma (-2.54%) etc.

Gland Pharma has a 51.83% promoter holding & 48.17% public holding.

FAQs about Gland Pharma

Gland Pharma is trading at 1414.50 as on 28 Apr, 2025 3:29:41 PM. This is -2.54% lower as compared to its previous closing price of 1451.35

The market capitalization of Gland Pharma is 23304.79 Cr as on 28 Apr, 2025 3:29:41 PM.

The average broker rating on Gland Pharma is Hold. The breakup of analyst rating is given below -

2 analysts have given a strong sell rating
3 analysts have given a sell rating
1 analysts have given a hold rating
0.00 analysts have given a buy rating
4 analysts have given a strong buy rating

The 52 wk high for Gland Pharma is 2220.95 whereas the 52 wk low is 1200.00

Gland Pharma can be analyzed on the following key metrics -

TTM P/E: 41.61
Sector P/E: 26.62
Dividend Yield: 1.38%
D/E ratio: -

Gland Pharma reported a net profit of 772.46 Cr in 2024.

Gland Pharma Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Gland Pharma Share Price

Price Range

Price Range

Key Metrics

Gland Pharma Analysis

Gland Pharma News

ICICI Pru MF buys 4 lakh shares of THIS pharma co despite 10% dip in April

Pharma stocks fall up to 5% as Donald Trump to announce pharma tariffs

Pharma shares rise up to 13% on Trump's tariff exemption; Gland Pharma lead gain

Indian pharma companies escape Trump’s reciprocal tariffs, for now

Gland Pharma Financials

Forecast

Forecast

Forecast

Gland Pharma Technical

Gland Pharma Peers

Gland Pharma Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Gland Pharma

MANAGEMENT

GLAND PHARMA SUMMARY

FAQs about Gland Pharma

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue